Biogen Accounts Payable vs Long Term Debt Total Analysis

BIIB Stock  USD 157.46  1.14  0.73%   
Biogen financial indicator trend analysis is way more than just evaluating Biogen Inc prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Biogen Inc is a good investment. Please check the relationship between Biogen Accounts Payable and its Long Term Debt Total accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Biogen Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.

Accounts Payable vs Long Term Debt Total

Accounts Payable vs Long Term Debt Total Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Biogen Inc Accounts Payable account and Long Term Debt Total. At this time, the significance of the direction appears to have strong relationship.
The correlation between Biogen's Accounts Payable and Long Term Debt Total is 0.7. Overlapping area represents the amount of variation of Accounts Payable that can explain the historical movement of Long Term Debt Total in the same time period over historical financial statements of Biogen Inc, assuming nothing else is changed. The correlation between historical values of Biogen's Accounts Payable and Long Term Debt Total is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Accounts Payable of Biogen Inc are associated (or correlated) with its Long Term Debt Total. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Long Term Debt Total has no effect on the direction of Accounts Payable i.e., Biogen's Accounts Payable and Long Term Debt Total go up and down completely randomly.

Correlation Coefficient

0.7
Relationship DirectionPositive 
Relationship StrengthSignificant

Accounts Payable

An accounting item on the balance sheet that represents Biogen obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Biogen Inc are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.

Long Term Debt Total

Most indicators from Biogen's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Biogen Inc current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Biogen Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.
At present, Biogen's Selling General Administrative is projected to increase significantly based on the last few years of reporting. The current year's Enterprise Value Over EBITDA is expected to grow to 19.32, whereas Tax Provision is forecasted to decline to about 128.5 M.
 2021 2022 2023 2024 (projected)
Gross Profit8.9B7.9B7.3B3.9B
Total Revenue11.0B10.2B9.8B10.3B

Biogen fundamental ratios Correlations

0.920.950.950.940.960.850.990.630.99-0.570.610.96-0.740.940.49-0.820.960.860.930.590.89-0.80.3-0.80.4
0.920.860.860.760.890.960.90.580.9-0.720.590.88-0.620.980.42-0.920.970.80.870.450.83-0.630.33-0.630.31
0.950.860.940.880.880.770.940.660.93-0.580.70.9-0.70.910.48-0.810.940.70.920.470.83-0.750.46-0.750.4
0.950.860.940.850.920.750.910.720.92-0.530.670.91-0.740.890.34-0.790.940.750.90.430.94-0.740.34-0.740.53
0.940.760.880.850.890.680.940.560.93-0.370.520.9-0.730.780.52-0.630.820.860.870.70.79-0.850.18-0.850.3
0.960.890.880.920.890.820.920.590.96-0.50.540.97-0.780.920.44-0.750.940.880.870.50.95-0.780.21-0.780.46
0.850.960.770.750.680.820.830.330.86-0.70.380.82-0.50.940.36-0.860.910.810.730.540.71-0.560.22-0.560.25
0.990.90.940.910.940.920.830.630.97-0.620.60.94-0.660.920.46-0.850.940.850.930.610.83-0.730.28-0.730.34
0.630.580.660.720.560.590.330.630.51-0.410.90.59-0.640.590.37-0.60.640.30.83-0.070.72-0.470.52-0.470.34
0.990.90.930.920.930.960.860.970.51-0.550.490.95-0.690.930.44-0.780.950.910.860.670.86-0.780.18-0.780.41
-0.57-0.72-0.58-0.53-0.37-0.5-0.7-0.62-0.41-0.55-0.38-0.540.14-0.72-0.130.87-0.68-0.46-0.55-0.26-0.470.06-0.20.06-0.19
0.610.590.70.670.520.540.380.60.90.49-0.380.52-0.60.610.48-0.60.640.180.84-0.140.62-0.550.83-0.550.36
0.960.880.90.910.90.970.820.940.590.95-0.540.52-0.750.910.4-0.790.930.870.880.530.9-0.740.18-0.740.35
-0.74-0.62-0.7-0.74-0.73-0.78-0.5-0.66-0.64-0.690.14-0.6-0.75-0.64-0.450.42-0.68-0.56-0.75-0.26-0.80.85-0.360.85-0.3
0.940.980.910.890.780.920.940.920.590.93-0.720.610.91-0.640.44-0.920.990.790.880.430.85-0.650.37-0.650.41
0.490.420.480.340.520.440.360.460.370.44-0.130.480.4-0.450.44-0.250.420.380.540.240.36-0.60.4-0.60.01
-0.82-0.92-0.81-0.79-0.63-0.75-0.86-0.85-0.6-0.780.87-0.6-0.790.42-0.92-0.25-0.9-0.64-0.82-0.32-0.710.37-0.370.37-0.35
0.960.970.940.940.820.940.910.940.640.95-0.680.640.93-0.680.990.42-0.90.790.910.440.89-0.690.37-0.690.45
0.860.80.70.750.860.880.810.850.30.91-0.460.180.87-0.560.790.38-0.640.790.670.780.76-0.65-0.17-0.650.28
0.930.870.920.90.870.870.730.930.830.86-0.550.840.88-0.750.880.54-0.820.910.670.350.85-0.760.53-0.760.34
0.590.450.470.430.70.50.540.61-0.070.67-0.26-0.140.53-0.260.430.24-0.320.440.780.350.32-0.53-0.35-0.53-0.06
0.890.830.830.940.790.950.710.830.720.86-0.470.620.9-0.80.850.36-0.710.890.760.850.32-0.710.25-0.710.52
-0.8-0.63-0.75-0.74-0.85-0.78-0.56-0.73-0.47-0.780.06-0.55-0.740.85-0.65-0.60.37-0.69-0.65-0.76-0.53-0.71-0.361.0-0.23
0.30.330.460.340.180.210.220.280.520.18-0.20.830.18-0.360.370.4-0.370.37-0.170.53-0.350.25-0.36-0.360.27
-0.8-0.63-0.75-0.74-0.85-0.78-0.56-0.73-0.47-0.780.06-0.55-0.740.85-0.65-0.60.37-0.69-0.65-0.76-0.53-0.711.0-0.36-0.23
0.40.310.40.530.30.460.250.340.340.41-0.190.360.35-0.30.410.01-0.350.450.280.34-0.060.52-0.230.27-0.23
Click cells to compare fundamentals

Biogen Account Relationship Matchups

Biogen fundamental ratios Accounts

201920202021202220232024 (projected)
Total Assets27.2B24.6B23.9B24.6B26.8B28.2B
Short Long Term Debt Total6.4B7.8B7.6B6.6B7.3B7.7B
Other Current Liab3.4B3.1B2.4B2.4B2.5B2.7B
Total Current Liabilities4.9B3.7B4.3B3.3B3.4B3.6B
Total Stockholder Equity13.3B10.7B11.0B13.4B14.8B15.5B
Property Plant And Equipment Net3.7B3.8B3.8B3.7B3.7B3.9B
Net Debt3.5B6.5B5.3B3.2B6.3B6.6B
Retained Earnings16.5B14.0B13.9B16.5B17.6B18.5B
Cash2.9B1.3B2.3B3.4B1.0B723.1M
Non Current Assets Total18.9B17.7B16.0B14.8B20.0B21.0B
Non Currrent Assets Other(3.2B)(1.4B)1.9B1.5B284.3M270.1M
Cash And Short Term Investments4.5B2.6B3.8B4.9B1.0B1.5B
Net Receivables1.9B2.3B2.0B2.1B2.1B2.2B
Common Stock Shares Outstanding187.4M161.3M149.6M146M145.6M283.0M
Liabilities And Stockholders Equity27.2B24.6B23.9B24.6B26.8B28.2B
Non Current Liabilities Total9.0B10.2B8.6B7.9B8.6B9.0B
Other Current Assets1.2B881.1M740.8M1.4B1.2B1.2B
Other Stockholder Equity(3.0B)(3.0B)(2.9B)(2.9B)(2.7B)(2.5B)
Total Liab13.9B13.9B12.9B11.2B12.0B12.6B
Property Plant And Equipment Gross3.7B3.8B3.8B3.7B6.1B6.4B
Total Current Assets8.4B6.9B7.9B9.8B6.9B7.2B
Accumulated Other Comprehensive Income(135.2M)(299M)(106.7M)(164.9M)(153.7M)(146.0M)
Intangible Assets3.5B3.1B2.2B1.9B8.4B8.8B
Accounts Payable530.8M454.9M589.2M491.5M403.3M423.5M
Short Term Investments2.3B1.6B1.3B1.5B1.5B0.0
Inventory804.2M1.1B1.4B1.3B2.5B2.7B
Other Liab4.2B2.4B2.0B1.3B1.5B969.6M
Other Assets3.2B4.2B3.4B1.7B1.9B2.0B
Long Term Debt4.5B7.4B6.3B6.3B6.8B7.1B
Property Plant Equipment3.2B3.4B3.4B3.3B3.8B2.1B
Good Will5.8B5.8B5.8B5.7B6.2B3.2B
Net Tangible Assets4.1B1.9B2.9B5.8B6.7B4.1B
Noncontrolling Interest In Consolidated Entity(4.1M)(14.2M)63.5M(9.5M)(8.6M)(8.1M)
Retained Earnings Total Equity16.5B14.0B13.9B16.5B18.9B11.5B

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Biogen Inc offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Biogen's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Biogen Inc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Biogen Inc Stock:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Biogen Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.
You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Biogen. If investors know Biogen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Biogen listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.02)
Earnings Share
11.05
Revenue Per Share
66.122
Quarterly Revenue Growth
(0.03)
Return On Assets
0.0499
The market value of Biogen Inc is measured differently than its book value, which is the value of Biogen that is recorded on the company's balance sheet. Investors also form their own opinion of Biogen's value that differs from its market value or its book value, called intrinsic value, which is Biogen's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Biogen's market value can be influenced by many factors that don't directly affect Biogen's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Biogen's value and its price as these two are different measures arrived at by different means. Investors typically determine if Biogen is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Biogen's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.